Market shares of various major aminoglucoside antibiotics have both ups and downs in recent years. Owing to its good curing effect and extremely low poisoning side effect, etimicin has maintained a rapid growth. Its market share made a sharp increase from 61.34% in 2004 to 77.55% in 2008. It has become the biggest winner among aminoglucoside antibiotics. Netilmicin has made a downturn under pressure. It has lost its original position and the market share made a constant reduction. Market shares of kanamycin and spectinomycin have also made a gradual reduction.
   The excellent curing effect of etimicin has helped promote the sales value of four Chinese major producers (Hangzhou Aida Pharmaceutical Co., Ltd., Changzhou Fang Yuan Pharmaceutical Co., Ltd., Jiangxi Jimin Kexin Group Co., Ltd. and Hainan Aike Pharmaceutical Group Co., Ltd.). The product will have a sound development trend in the next few years.

See more by subscription